Brokers Offer Predictions for LENZ Therapeutics, Inc.’s FY2028 Earnings (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at Leerink Partnrs cut their FY2028 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a report released on Wednesday, May 8th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $2.50 for the year, down from their prior forecast of $2.70. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($1.89) per share.

A number of other research firms have also recently commented on LENZ. William Blair began coverage on LENZ Therapeutics in a report on Monday, April 15th. They issued an “outperform” rating on the stock. Piper Sandler began coverage on shares of LENZ Therapeutics in a report on Wednesday, March 27th. They issued an “overweight” rating and a $28.00 target price for the company. SVB Leerink assumed coverage on shares of LENZ Therapeutics in a research note on Monday, April 15th. They set an “outperform” rating and a $32.00 price objective for the company. Finally, Citigroup began coverage on shares of LENZ Therapeutics in a report on Wednesday, April 10th. They set a “buy” rating and a $34.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $31.33.

LENZ Therapeutics Stock Up 3.8 %

Shares of LENZ Therapeutics stock traded up $0.58 on Friday, hitting $15.98. The company’s stock had a trading volume of 89,805 shares, compared to its average volume of 80,114. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $29.82. The firm has a market cap of $58.33 million, a PE ratio of -0.99 and a beta of 0.33.

Insider Transactions at LENZ Therapeutics

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. purchased 998,009 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were acquired at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the completion of the purchase, the director now owns 3,319,339 shares of the company’s stock, valued at approximately $49,889,665.17. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 38.40% of the stock is currently owned by insiders.

Institutional Trading of LENZ Therapeutics

Several hedge funds have recently bought and sold shares of LENZ. BNP Paribas Financial Markets bought a new stake in LENZ Therapeutics in the 1st quarter valued at about $362,000. Jennison Associates LLC purchased a new stake in shares of LENZ Therapeutics during the first quarter valued at approximately $3,009,000. Marquette Asset Management LLC purchased a new stake in LENZ Therapeutics in the first quarter worth $131,000. Finally, BML Capital Management LLC purchased a new stake in LENZ Therapeutics in the first quarter worth $1,427,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.